Gaudencio Pavia, MD
Internal Medicine · Las Cruces, NMNPI 1881760957
Payments from drug & device makers
Across 13 payments — averaging $38.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$246
- Bristol Myers Squibb$86
- Abbott$54
- AstraZeneca$47
- Xeris Pharmaceuticals, Inc.$19
- GSK$19
- plus $28 from 2 others
What the payments were for
- Food & beverage$500100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 2 | $246 |
| Bristol Myers Squibb | 1 | $86 |
| Abbott | 3 | $54 |
| AstraZeneca | 3 | $47 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| GSK | 1 | $19 |
| Exact Sciences | 1 | $15 |
| Axsome Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$147
How this compares
$500 in reported general payments places this provider in the 75th percentile of 578 internal medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 46 | $123,881 |
| EliquisApixaban | 28 | $45,001 |
| OzempicSemaglutide | 35 | $44,173 |
| MounjaroTirzepatide | 16 | $42,336 |
| JardianceEmpagliflozin | 18 | $30,728 |
| Humalog Kwikpen U-100Insulin Lispro | 30 | $13,375 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $12,907 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $12,753 |
| JanuviaSitagliptin Phosphate | 14 | $11,730 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $10,277 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $8,963 |
| Levemir FlexpenInsulin Detemir | 16 | $5,983 |
| Atorvastatin Calcium | 444 | $5,712 |
| Gabapentin | 287 | $5,350 |
| Levothyroxine Sodium | 432 | $4,843 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Las Cruces
- Ann MercerLas Cruces$6K
- Sangeeth PaiLas Cruces$4K
- Syed AhmedLas Cruces$3K
- Azhar ZahirLas Cruces$3K
- Talha KhanLas Cruces$3K
- Jobin PhiliposeLas Cruces$2K
- Louis BeneventoLas Cruces$2K
- Edna JuarezLas Cruces$2K
- Michelle ValentineAlbuquerque$12.7M
- Linda GorgosSanta Fe$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.